Chinese expert consensus on neoadjuvant therapy for hepatocellular carcinoma (2023 edition).
10.3760/cma.j.cn112139-20230914-00121
- Collective Name:Alliance of Chinese Expert Consensus on Neoadjuvant Therapy for Hepatocellular Carcinoma;Committee of Digestive Surgery of Chinese Research Hospital Association;Committee of Liver Cancer, Chinese Anti-Cancer Association
- Publication Type:Review
- MeSH:
Humans;
Antineoplastic Agents/therapeutic use*;
Carcinoma, Hepatocellular/surgery*;
China;
Consensus;
Liver Neoplasms/pathology*;
Neoadjuvant Therapy
- From:
Chinese Journal of Surgery
2023;61(12):1035-1045
- CountryChina
- Language:Chinese
-
Abstract:
Recurrence of hepatocellular carcinoma (HCC) after surgery is a major factor affecting the efficacy of the treatment of patients. Neoadjuvant treatment is an effective therapeutic method to reduce postoperative recurrence and prolong patient survival. However,there is no generally accepted neoadjuvant treatment regimen that has been proven to be effective so far. Recently,with the progress in systemic antitumor therapies,represented by targeted molecular agents and immune checkpoint inhibitors,and the improvement in local regional therapies,these treatment approaches have shown promising efficacy and safety in the field of neoadjuvant treatment for HCC. Under the organizational leadership of Committee of Digestive Surgery of Chinese Research Hospital Association and Committee of Liver Cancer of Chinese Anti-Cancer Association,Alliance of Chinese Expert Consensus on Neoadjuvant Therapy for Hepatocellular Carcinoma has discussed and revised several times and finally formulated the Chinese expert consensus on neoadjuvant therapy for hepatocellular carcinoma (2023 edition). This consensus aimed to review the Chinese characteristics of the diagnosis and treatment of HCC,to provide specific guidance and suggestions for preoperative treatment strategies for HCC,and further promote the management of the clinical pathway for neoadjuvant treatment of HCC.
